Evidence map›Paper›PMID 29473914›Full record

ReviewMaterials (Basel, Switzerland)2018

Fe₃O₄ Nanoparticles in Targeted Drug/Gene Delivery Systems.

Lazhen Shen, Bei Li, Yongsheng Qiao

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. FeACS omega · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Bioconversion of FePharmaceuticals (Basel, Switzerland) · 2025
    Article
  17. Article
  18. Anxiety of microbially synthesized FeApplied microbiology and biotechnology · 2025
    Article
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lazhen ShenSchool of Chemistry and Environmental Engineering, Institute of Applied Chemistry, Shanxi Datong University, Datong 037009, China. shenlazhen@163.com.
Bei LiSchool of Chemistry and Environmental Engineering, Institute of Applied Chemistry, Shanxi Datong University, Datong 037009, China. 13653621281@163.com.
Yongsheng QiaoDepartment of Chemistry, Xinzhou Teachers University, Xinzhou 034000, China. dtdxqys@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fe₃O₄ nanoparticles (NPs), the most traditional magnetic nanoparticles, have received a great deal of attention in the biomedical field, especially for targeted drug/gene delivery systems, due to their outstanding magnetism, biocompatibility, lower toxicity, biodegradability, and other features. Naked Fe₃O₄ NPs are easy to aggregate and oxidize, and thus are often made with various coatings to realize superior properties for targeted drug/gene delivery. In this review, we first list the three commonly utilized synthesis methods of Fe₃O₄ NPs, and their advantages and disadvantages. In the second part, we describe coating materials that exhibit noticeable features that allow functionalization of Fe₃O₄ NPs and summarize their methods of drug targeting/gene delivery. Then our efforts will be devoted to the research status and progress of several different functionalized Fe₃O₄ NP delivery systems loaded with chemotherapeutic agents, and we present targeted gene transitive carriers in detail. In the following section, we illuminate the most effective treatment systems of the combined drug and gene therapy. Finally, we propose opportunities and challenges of the clinical transformation of Fe₃O₄ NPs targeting drug/gene delivery systems.

Indexed as

coatingdrug/gene delivery systemsFe3O4 nanoparticlesfunctionalizationsynthesis

Identifiers

PMID29473914
PMCPMC5849021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.